Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silence Therapeutics Plc ADR
(NQ:
SLN
)
15.53
-0.31 (-1.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Silence Therapeutics Plc ADR
< Previous
1
2
3
4
Next >
Analyst Expectations For Silence Therapeutics's Future
August 16, 2024
Via
Benzinga
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
August 15, 2024
Silence Therapeutics just reported results for the second quarter of 2024.
Via
InvestorPlace
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 15, 2024
From
Silence Therapeutics plc
Via
Business Wire
The 3 Best Gene Editing Stocks to Buy in August 2024
August 07, 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.
Via
InvestorPlace
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
July 25, 2024
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.
Via
InvestorPlace
The Analyst Landscape: 6 Takes On Silence Therapeutics
June 20, 2024
Via
Benzinga
What 7 Analyst Ratings Have To Say About Silence Therapeutics
May 17, 2024
Via
Benzinga
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
April 22, 2024
Via
Benzinga
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
June 27, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
June 24, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
June 20, 2024
From
Silence Therapeutics plc
Via
Business Wire
What 4 Analyst Ratings Have To Say About Silence Therapeutics
March 13, 2024
Via
Benzinga
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
May 30, 2024
From
Silence Therapeutics plc
Via
Business Wire
SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024
May 16, 2024
Silence Therapeutics just reported results for the first quarter of 2024.
Via
InvestorPlace
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
May 16, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
April 30, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
April 29, 2024
From
Silence Therapeutics plc
Via
Business Wire
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
April 11, 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
Via
InvestorPlace
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
April 08, 2024
From
Silence Therapeutics plc
Via
Business Wire
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
March 14, 2024
Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.
Via
Benzinga
What's Going On With Silence Therapeutics Stock Today?
March 13, 2024
Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of...
Via
Benzinga
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
March 13, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
March 13, 2024
From
Silence Therapeutics plc
Via
Business Wire
Earnings Scheduled For March 13, 2024
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
February 28, 2024
From
Silence Therapeutics plc
Via
Business Wire
Earnings Scheduled For March 12, 2024
March 12, 2024
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.
Via
Benzinga
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
February 23, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
February 05, 2024
From
Silence Therapeutics plc
Via
Business Wire
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
January 31, 2024
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.